Positron Emission Tomography (PET)

ApprovedSmall molecule

CCentre Hospitalier Universitaire de Saint Etienne

Positron Emission Tomography (PET) is one of 52 small molecule programs targeting Anorexia Nervosa. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anorexia NervosaActive, not recruiting

Bulimia NervosaActive, not recruiting

Anorexia NervosaPreclinical

Active, not recruiting

Bulimia NervosaApproved

Active, not recruiting

Competition

Competitive Landscape

53 competitors in Anorexia Nervosa

#DrugCompanyPhaseTrials

Zyprexa

MMODAG GmbH

Approved

6 2

Abilify

Otsuka

Approved

2 3

Risperdal

WWim Janssens

Approved

1 4

Prometrium

Pitocin

Remeron

Marinol

Alnylam Pharmaceuticals

Phase 3

1 8

Prolia

Amgen

Phase 3

1 9

Zometa

Pfizer

Phase 3

1 10

Aricept

Eisai

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Anorexia Nervosa1 trial

Evaluation of Brain Opioid Receptor Activity in Anorexia Nervosa : a PET [11C]Diprenorphine Study

Completed·—·N/A·NCT02524301·53 enrolled

Bulimia Nervosa1 trial

Evaluation of the Efficacy of Serotoninergic Antidepressants in Bulimia Nervosa, According to Brain Serotonin Profile Determined by Positron Emission Tomography With [18F] MPPF.

Completed·—·Phase 4·NCT02359513·51 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Positron Emission Tomography (PET). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Positron Emission Tomography (PET) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Positron Emission Tomography (PET). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centre Hospitalier Universitaire de Saint Etienne company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: CCentre Hospitalier Universitaire de Saint Etienne

Positron Emission Tomography (PET)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Anorexia Nervosa1 trial

Bulimia Nervosa1 trial

References

Drug Info

Quick Facts

Related News